These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Absence of Relevant Thermal Conversion of Cannabidiol to Tetrahydrocannabinol in E-Cigarette Vapor and Low-Tetrahydrocannabinol Cannabis Smoke. Hindelang P; Scharinger A; Golombek P; Laible M; Tamosaite S; Walch SG; Lachenmeier DW Cannabis Cannabinoid Res; 2022 Oct; 7(5):616-620. PubMed ID: 36169637 [No Abstract] [Full Text] [Related]
25. Acute effects of Δ Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products. Zamarripa CA; Tilton HE; Lin S; Cone EJ; Winecker RE; Flegel RR; Kuntz D; Beals M; Jacques M; Clark M; Welsh ER; Wagner L; Bonn-Miller MO; Vandrey R; Spindle TR J Anal Toxicol; 2024 Mar; 48(2):81-98. PubMed ID: 38217086 [TBL] [Abstract][Full Text] [Related]
27. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study. Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109 [TBL] [Abstract][Full Text] [Related]
28. Effects of oral Δ9-tetrahydrocannabinol and cannabidiol combinations on a sustained attention task in rats. Moore CF; Davis CM; Sempio C; Klawitter J; Christians U; Weerts EM Exp Clin Psychopharmacol; 2023 Oct; 31(5):881-887. PubMed ID: 36634015 [TBL] [Abstract][Full Text] [Related]
29. Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats. Gabaglio M; Zamberletti E; Manenti C; Parolaro D; Rubino T Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445602 [TBL] [Abstract][Full Text] [Related]
30. The Dark Side of Cannabidiol: The Unanticipated Social and Clinical Implications of Synthetic Δ Geci M; Scialdone M; Tishler J Cannabis Cannabinoid Res; 2023 Apr; 8(2):270-282. PubMed ID: 36264171 [No Abstract] [Full Text] [Related]
31. What Do You Know About Maryjane? A Systematic Review of the Current Data on the THC:CBD Ratio. Zeyl V; Sawyer K; Wightman RS Subst Use Misuse; 2020; 55(8):1223-1227. PubMed ID: 32124675 [No Abstract] [Full Text] [Related]
32. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Englund A; Oliver D; Chesney E; Chester L; Wilson J; Sovi S; De Micheli A; Hodsoll J; Fusar-Poli P; Strang J; Murray RM; Freeman TP; McGuire P Neuropsychopharmacology; 2023 May; 48(6):869-876. PubMed ID: 36380220 [TBL] [Abstract][Full Text] [Related]
33. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity. Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455 [TBL] [Abstract][Full Text] [Related]
34. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290 [TBL] [Abstract][Full Text] [Related]
35. Differential inflammatory profile in the lungs of mice exposed to cannabis smoke with varying THC:CBD ratio. Haidar Z; Traboulsi H; Eidelman DH; Baglole CJ Arch Toxicol; 2023 Jul; 97(7):1963-1978. PubMed ID: 37179517 [TBL] [Abstract][Full Text] [Related]
36. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. Abi-Jaoude E; Bhikram T; Parveen F; Levenbach J; Lafreniere-Roula M; Sandor P Cannabis Cannabinoid Res; 2023 Oct; 8(5):835-845. PubMed ID: 36040329 [No Abstract] [Full Text] [Related]
37. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154 [TBL] [Abstract][Full Text] [Related]
38. Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence. Mokrysz C; Shaban NDC; Freeman TP; Lawn W; Pope RA; Hindocha C; Freeman A; Wall MB; Bloomfield MAP; Morgan CJA; Nutt DJ; Curran HV Psychol Med; 2021 Sep; 51(12):2134-2142. PubMed ID: 32340632 [TBL] [Abstract][Full Text] [Related]
39. Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study. Oliver D; Englund A; Chesney E; Chester L; Wilson J; Sovi S; Wigroth S; Hodsoll J; Strang J; Murray RM; Freeman TP; Fusar-Poli P; McGuire P Addiction; 2024 Feb; 119(2):322-333. PubMed ID: 37821096 [TBL] [Abstract][Full Text] [Related]
40. Chemical profiling of Cannabis varieties cultivated for medical purposes in southeastern Brazil. Carvalho VM; de Almeida FG; de Macêdo Vieira AC; Rocha ED; Cabral LM; Strongin RM Forensic Sci Int; 2022 Jun; 335():111309. PubMed ID: 35462181 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]